Following up on multiple actions taken this year in the name of controlling drug prices, CMS on Nov. 26 issued a proposed rule making changes to the Medicare Advantage and Part D programs that would take effect in 2020. Key provisions in CMS’s latest drug pricing rule (83 Fed. Reg. 62152, Nov. 30, 2018) include […]
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.